Development and commercialization of a new molecularly targeted imaging agent for multiple myeloma
Ended Project Grant Awarded Last action
- Award ID
- R42CA257797
- Recipient
-
Sarya LLC UEI X7KLFUPEEJN8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,373,508
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Missouri, USA
Award details come from USAspending.gov.
Description
- Abstract
- Sarya LLC (sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this fast-track sttr is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2ND most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate detection is critical for enhancing survival in MM patients. Traditional skeletal survey and bone scans have sensitivity limitations for osteolytic lesions manifested in MM. Positron emission tomography (pet) performed with a pet radiopharmaceutical (imaging agent) is a sensitive, quantitative and non-invasive clinical imaging technology to accurately detect, localize and phenotype MM cells throughout the body. 18F-fluorodeoxyglucose (FDG) is the only FDA-approved pet imaging agent for MM. Unfortunately, MM cells express low levels of glut-1 transporter and hexokinase, which are required for FDG uptake and retention. Additionally MM bone marrow harbors FDG-avid inflammatory cells. There is an unmet need for molecularly targeted, sensitive and specific MM imaging agents that can accurately stage and restage MM, identify high-risk MM patients, guide personalized MM treatment, and evaluate clinical response to treatment. The product of this sttr will be a specific and sensitive pet imaging agent (64CU-LLP2A) for MM. Published data and ongoing first-in-human trial results have significantly informed the phase i and II aims of this proposal. The phase i segment consists of two specific aims: (1) perform dose escalation and single dose toxicity testing in mice. (2) compile data for new dose and submit amendment of eind to FDA. Three milestones will be met in phase i: (1) a new mass will be selected based on no-observed-adverse-effect level (noael), i.e. clinical signs of organ toxicity (vehicle VS experimental). (2) based on the new determined mass, and in vivo preclinical image quality data, a new specific activity (CI/MOL) will be established. (3) obtain FDA approval of sarya sponsored amended eind application. The phase II segment involves a clinical trial and has one specific aim: quantify the efficacy of 64CU-LLP2A-pet imaging for detecting active MM in humans in a prospective imaging trial. Phase II milestones are: (1) demonstrate high detection rates (% of scans that are positive for a focal lesion, p
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $974,650 | |
| Amendment | $974,650 | |
| Amendment | $974,650 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,025,350 | |
| Amendment | $1,025,350 | |
| Original award | $398,858 |
Show all 16
Quick answers
Who received award R42CA257797?
R42CA257797 was awarded to Sarya LLC by National Cancer Institute (National Institutes of Health) on May 1, 2021.
How much is award R42CA257797 worth?
$5,373,508 has been obligated on R42CA257797.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award